肿瘤细胞治疗研究
英文原题：Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
设计用于识别特定肿瘤抗原的过继性嵌合抗原受体（CAR）T 细胞已在癌症治疗中显示出有前景的结果。
针对特定肿瘤抗原设计的过继嵌合抗原受体（CAR）T细胞已在癌症治疗中显示出良好前景。CAR-T治疗血液系统疾病具有显著临床疗效，但其在胶质母细胞瘤（GBM）等实体瘤中的开发仍受到肿瘤异质性、免疫抑制性肿瘤微环境和细胞迁移困难的阻碍。临床试验已尝试靶向IL13Rα2、EGFRvIII和HER2等多种肿瘤抗原，但疗效有限。本文综述GBM CAR-T临床试验的现状和潜在靶抗原，并总结增强疗效的机制与策略，探讨该疗法面临的挑战及未来前景。
Adoptive chimeric antigen receptor (CAR) T cells designed to recognize specific tumor antigens have shown promising results in cancer therapy. While CAR T cell therapy has demonstrated notable clinical effectiveness for hematologic disease, efforts to develop therapies for solid tumors, including glioblastoma (GBM), have been hampered by heterogeneity, an immunosuppressive tumor microenvironment, and difficulty in trafficking. Several specific tumor antigens, such as IL13R 2, EGFRvIII, and HER2, have been attempted in clinical trials; however, limited efficacy has been observed. In this review, we discuss the current status of CAR T therapy for GBM in clinical trials and highlight the potential target antigens for CAR T cells. Additionally, we summarize the mechanisms used to enhance their efficacy and explore the challenges and future prospects of CAR T cell therapy for GBM.
MEMBER ACCOUNT
登录成功会直接打开下一页。
